Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PODXL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PODXL ECD-Fc / Mutant Protein HEK293 expressed for native glycosylation, high purity (>95%), endotoxin controlled. Sequence Verified. |
View PODXL Products |
| Gene Delivery | PODXL Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry validation. |
View PODXL Products |
| Benchmark Ab | Anti-PODXL Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View PODXL Products |
| Validator | PODXL siRNA Set Target-specific knockdown verification in target-expressing tumor cell lines. |
View PODXL Products |
| Related Target A | CD34 Sialomucin family homolog; critical for specificity and counter-screening assays. |
View CD34 Products |
| Related Target B | CD147 (EMMPRIN) Co-expressed metastasis driver; synergistic partner in aggressive solid tumors. |
View CD147 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Tumor-Specific Glycoform Targeting | HEK293 host expression ensures native mammalian post-translational modifications (sialylation/O-glycosylation). |
| Cross-Species Cross-Reactivity Screening | Human, Cynomolgus, and Mouse PODXL ortholog proteins available with strictly verified sequence integrity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| Off-Target Binding to Homologs | CD34 homolog panel proteins available for rigorous counter-screening. |
Live Podocalyxin (PODXL) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PODXL therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies targeting tumor-associated antigens reach clinical bottlenecks, PODXL has emerged as a high-value target due to its upregulation in aggressive, metastatic solid tumors (including pancreatic, glioblastoma, and ovarian cancers) and its correlation with poor patient survival.
The next wave of R&D is heavily focused on targeting tumor-specific glycoforms of PODXL to spare normal tissues—particularly renal podocytes, where PODXL plays a critical physiological role in vascular filtration. Consequently, generating antibodies that selectively bind to the hypoglycosylated or aberrantly glycosylated PODXL found in tumor microenvironments is the key to unlocking its therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Oncology Biotechs, Academic Consortia | Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer | Internalization Assay (Need high-purity, native glycosylated ECD-Fc) |
| Tumor-Glycan Targeted mAbs | Specialized Glyco-Oncology Firms | Glioblastoma, Breast Cancer Metastasis | Glycan-Profiling & Binding Affinity (Need HEK293-expressed antigen) |
| CAR-T / Cell Therapies | Cell Therapy Developers | Solid Tumors (Refractory) | Target Cell Line Generation (Need High-Titer Lentivirus for stable expression) |